{"id":"bendamustine-hydrochloride-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL1201734","moleculeType":"Small molecule","molecularWeight":"394.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bendamustine functions as a bifunctional alkylating agent that covalently binds to DNA, creating interstrand and intrastrand cross-links that prevent DNA replication and transcription. This leads to apoptosis in malignant cells. Unlike classical alkylating agents, bendamustine also has immunomodulatory properties that may enhance its anti-tumor activity.","oneSentence":"Bendamustine is an alkylating agent that cross-links DNA strands, causing cell death in rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:55.303Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Non-Hodgkin's lymphoma (NHL)"},{"name":"Hodgkin's lymphoma"}]},"trialDetails":[{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT03696784","phase":"PHASE1","title":"Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-03-12","conditions":"Lymphoma, Lymphoma, B-Cell, Immune System Diseases","enrollment":19},{"nctId":"NCT04083495","phase":"PHASE2","title":"CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-09-17","conditions":"Peripheral T Cell Lymphoma","enrollment":20},{"nctId":"NCT05451771","phase":"PHASE1, PHASE2","title":"Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis","status":"RECRUITING","sponsor":"Rajshekhar Chakraborty, MD","startDate":"2022-10-26","conditions":"AL Amyloidosis","enrollment":53},{"nctId":"NCT06757478","phase":"","title":"A Clinical Study on the Combination of Mitoxantrone Liposome Injection, Bendamustine, Etoposide, and Cytarabine for Pretreatment of Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-05-01","conditions":"Lymphoma Patient","enrollment":30},{"nctId":"NCT03593018","phase":"PHASE3","title":"Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients with Relapsed or Refractory AITL","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2018-11-09","conditions":"Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma","enrollment":86},{"nctId":"NCT06363994","phase":"PHASE3","title":"A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL","status":"RECRUITING","sponsor":"InnoCare Pharma Inc.","startDate":"2024-05-29","conditions":"Mantle Cell Lymphoma","enrollment":476},{"nctId":"NCT02626455","phase":"PHASE3","title":"Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-01-06","conditions":"Lymphoma, Non-Hodgkin","enrollment":551},{"nctId":"NCT00877214","phase":"PHASE3","title":"Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jurgen Barth","startDate":"2009-04-01","conditions":"Follicular Lymphomas, Immunocytomas, Marginal Zone Lymphomas","enrollment":1272},{"nctId":"NCT04510636","phase":"PHASE2","title":"Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-12-20","conditions":"Classical Hodgkin Lymphoma, Relapsed Cancer, Refractory Cancer","enrollment":37},{"nctId":"NCT03900377","phase":"PHASE1, PHASE2","title":"Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma","status":"COMPLETED","sponsor":"SymBio Pharmaceuticals","startDate":"2019-04-01","conditions":"Lymphoma, B-cell, Diffuse","enrollment":37},{"nctId":"NCT02257242","phase":"PHASE1","title":"Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma","status":"COMPLETED","sponsor":"Brown University","startDate":"2017-05-10","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Mantle-Cell","enrollment":11},{"nctId":"NCT04897477","phase":"PHASE1, PHASE2","title":"Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-04-22","conditions":"Non-hodgkin Lymphoma,B Cell","enrollment":30},{"nctId":"NCT01088048","phase":"PHASE1","title":"Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03-25","conditions":"Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":241},{"nctId":"NCT02576275","phase":"PHASE3","title":"A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)","status":"WITHDRAWN","sponsor":"SecuraBio","startDate":"2015-12","conditions":"Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma","enrollment":""},{"nctId":"NCT02434484","phase":"","title":"Symbenda Post-Marketing Surveillance (PMS)","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2018-07-04","conditions":"Lymphoma, Non-Hodgkin, Lymphocytic Leukemia, Multiple Myeloma","enrollment":84},{"nctId":"NCT04569838","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2012-05","conditions":"Indolent B-Cell Non-Hodgkin's Lymphomas","enrollment":91},{"nctId":"NCT01490723","phase":"PHASE2","title":"Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-01","conditions":"Leukemia, Lymphoma","enrollment":20},{"nctId":"NCT01077518","phase":"PHASE3","title":"Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08-26","conditions":"Lymphoma, Follicular","enrollment":346},{"nctId":"NCT01831505","phase":"PHASE1","title":"Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents","status":"COMPLETED","sponsor":"Presage Biosciences","startDate":"2012-11","conditions":"Lymphoma","enrollment":4},{"nctId":"NCT01109264","phase":"PHASE2","title":"Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2010-03","conditions":"Chronic Lymphocytic Leukemia","enrollment":147},{"nctId":"NCT00872976","phase":"PHASE1","title":"Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2009-05","conditions":"Chronic Lymphocytic Leukemia","enrollment":""},{"nctId":"NCT00920855","phase":"PHASE1, PHASE2","title":"Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Cephalon","startDate":"2009-06","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT01657955","phase":"PHASE3","title":"Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia","status":"UNKNOWN","sponsor":"Shandong Lanjin Pharmaceuticals Co.,Ltd","startDate":"2011-01","conditions":"Chronic Lymphocytic Leukemia, Leukemia, Neoplasms","enrollment":96},{"nctId":"NCT01570049","phase":"PHASE3","title":"Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Shandong Lanjin Pharmaceuticals Co.,Ltd","startDate":"2010-04","conditions":"Non-Hodgkin Lymphoma by Clinical Course","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["bendamustine hydrochloride"],"phase":"phase_3","status":"active","brandName":"Bendamustine hydrochloride injection","genericName":"Bendamustine hydrochloride injection","companyName":"Jiangsu Simcere Pharmaceutical Co., Ltd.","companyId":"jiangsu-simcere-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bendamustine is an alkylating agent that cross-links DNA strands, causing cell death in rapidly dividing cancer cells. Used for Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}